1. Home
  2. CNDT vs MNPR Comparison

CNDT vs MNPR Comparison

Compare CNDT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Conduent Incorporated

CNDT

Conduent Incorporated

HOLD

Current Price

$2.07

Market Cap

448.6M

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$68.00

Market Cap

421.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNDT
MNPR
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
448.6M
421.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CNDT
MNPR
Price
$2.07
$68.00
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$101.42
AVG Volume (30 Days)
1.2M
325.4K
Earning Date
02-11-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,072,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$24.00
52 Week High
$4.90
$105.00

Technical Indicators

Market Signals
Indicator
CNDT
MNPR
Relative Strength Index (RSI) 56.12 49.18
Support Level $1.98 $57.86
Resistance Level $2.10 $66.65
Average True Range (ATR) 0.08 5.60
MACD 0.01 0.95
Stochastic Oscillator 90.38 78.78

Price Performance

Historical Comparison
CNDT
MNPR

About CNDT Conduent Incorporated

Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: